<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Lytix Biopharma And KAEL-GemVax Announce Joint Clinical Trial To Combine LTX-315 And GV1001 Cancer Immunotherapy</title>
	<atom:link href="http://pharmainvestingnews.com/2009/06/lytix-biopharma-and-kael-gemvax-announce-joint-clinical-trial-to-combine-ltx-315-and-gv1001-cancer-immunotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmainvestingnews.com/2009/06/lytix-biopharma-and-kael-gemvax-announce-joint-clinical-trial-to-combine-ltx-315-and-gv1001-cancer-immunotherapy/</link>
	<description>Pharmaceutical Industry Investment News, Tips, Information and Reviews</description>
	<pubDate>Wed, 08 Sep 2010 12:37:50 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.5</generator>
	</channel>
</rss>
